AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04655183 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Niraparib will be administered orally once daily at the RDE as determined in Part 1 of this study.
Study NCT04655183 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M4344
Description: M4344 will be administered at a dose and schedule that was determined as RDE in Part 1A in combination with niraparib.
Study NCT04655183 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Niraparib will be administered orally, once daily. Dose of niraparib will be escalated beyond the dose in Part 1A.
Study NCT04655183 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Niraparib will be administered as single agent at the approved dose.
Study NCT01830764 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Red Light (PDT)
Description: LTS, 0.3% applied topically followed by red light dose (75 J/cm2 or 150 J/cm2)
Study NCT00629317 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Moisturizer
Description: Cetaphil cream(For 3 hours) + Aktilite ( Photodynamic Therapy for 8 minutes)
Study NCT00629317 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methyl Aminolevulinate
Description: Methyl Aminolevulinate cream for 3 hours before Photodynamic therapy ( Aktilite)
Study NCT02230709 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry Needling
Description: Needling with acupuncture needle in a myofascial trigger point.
Study NCT02230709 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TENS and dry needling
Description: Application of TENS current after dry needling technique
Study NCT03918447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bardoxolone methyl oral capsule
Description: Bardoxolone methyl capsules dose escalated from 5 mg to a maximum of 20 or 30 mg, depending on baseline proteinuria status.
Study NCT03918447 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Capsule containing an inert placebo
Study NCT01797562 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Panels 1.3, 2.2 and 3.2 experimental allergens
Description: Three allergen panels will be applied to the upper backs of study subjects and will be worn for 48 hours. Allergen test sites will be evaluated at 3, 4, 7(±1) and 21(±2) days post application.
Study NCT02185365 — intervention group
Intervention type: RADIATION
Intervention: Magnetic Resonance Imaging (MRI)
Description: Patients will undergo 2 different MRIs of the affected hip. Both MRIs assess hip cartilage degeneration. A contrast agent, Gadolinium, will be used to visualize cartilage during the MRI. The contrast agent is injected through an intravenous (a small plastic tube inserted into a vein in the patients' arm) before the MRI.
Study NCT00849745 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nonmyeloablative allogeneic stem cell transplant
Description: Prior to receiving Campath-1H, patients will be premedicated with Benadryl 50 mg IV or PO, and acetaminophen 650 mg orally. Hydrocortisone 100 mg IV is given on the first day of Campath. The preparative regimen will begin on day -5 and consist of 4 days of daily fludarabine at 30 mg/m2/d infused over 30 minutes, cyclophosphamide 500 mg/m2/d infused over 1 hour, 5 days of Campath-1H at 20 mg/d in 250 ml of D5 normal saline or normal saline infused over 3 hours. The mixed dosage of chemotherapy may be rounded off to within +/- 5% of the calculated dose, and doses of fludarabine and cyclophosphamide will be based on adjusted ideal body weight. IV hydration and diuretics will be used to maintain adequate urine output during and after administration of cyclophosphamide.
Study NCT03879083 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Addition of palatal rugae to the complete denture surface
Description: The addition and reproduction of the patient's own palatal rugae to the complete maxillary denture palatal surface.
Study NCT03879083 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The removal of the palatal rugae from the complete denture surface
Description: The removal of the palatal rugae from the complete maxillary denture palatal surface to become a smooth surface
Study NCT02115178 — intervention group
Intervention type: OTHER
Intervention: Lithotomy or Prone position
Description: The surgery, haemodynamic measurements will be performed in Lithotomy or Prone position
Study NCT04156178 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD20-CD19 cCAR T cells
Description: CD20-CD19 cCAR T cells administered to patients, will be either fresh or thawed CAR T cells by IV injection after receiving lymphodepleting chemotherapy
Study NCT00899379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rizatriptan benzoate
Description: Rizatriptan 10 mg p.o. at onset of moderate to severe migraine headache
Study NCT00899379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Placebo
Description: Placebo to Rizatriptan, Oral Tablet
Study NCT04151706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD8+ Memory T Cell Infusion
Description: Allogeneic phenotypic CD8+ memory T cells from HLA matched donors infused at the time of hematopoietic cell transplantation
Study NCT04151706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: 5 mg/kg/day: IV for 2 consecutive days (days -6 to -5)
Study NCT04151706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 25 mg/m2/day: IV for 5 consecutive days (days -6 to -2)
Study NCT04151706 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hyperfractionated TBI
Description: Administered in 11 fractions of 125 cGy over 4 days (Total dose of 1375 cGy)
Study NCT04151706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: 6 mg/kg/dose Q24h IV. Infused over 3 hours. 1 dose per day x 4 consecutive days x 3.6 mg/kg/dose = 14.4 mg/kg
Study NCT04151706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 60 mg/kg/dose Q24h IV. Infused over 2 hours. 1 dose per day x 2 consecutive days x 60 mg/kg/dose = 120 mg/kg
Study NCT01204593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INSULIN GLARGINE
Description: Pharmaceutical form: solution for injection Route of administration: sub-cutaneous Dose regimen: once a day at bedtime
Study NCT01204593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INSULIN GLULISINE
Description: Pharmaceutical form: solution for injection Route of administration: sub-cutaneous Dose regimen: three times a day, preferably just before the meal
Study NCT02084355 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral oxycodone
Study NCT02084355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral oxycodone
Study NCT02084355 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral hydromorphone
Study NCT02084355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral hydromorphone
Study NCT02084355 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fentanyl patch
Study NCT02084355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fentanyl patch
Study NCT02166047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vesatolimod
Description: Vesatolimod tablet administered orally
Study NCT02166047 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match vesatolimod tablet administered orally
Study NCT03134976 — intervention group
Intervention type: DRUG
Intervention: Levothyroxine
Description: Immediately post-operatively, all patients undergoing laryngectomy will be started on established weight-based dosing of levothyroxine administered intravenously due to the variable enteral absorption in post-operative patients including those on continuous tube feed regimens. Standard enteral dose is 1.6 mcg/kg/day. Eighty percent of this dose (1.3 mcg/kg/day) will be given IV to account for the increased bioavailability of IV levothyroxine compared to enteral levothyroxine. The maximum dose will be 200 mcg/day. Patients previously on levothyroxine at doses lower than the above dose will changed to the aforementioned standard dose. Patients on higher doses of levothyroxine pre-operatively will be maintained on on their current dosing.
Study NCT01730742 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neuroeconomics task
Description: After a night of wakefulness, participants performed the neuroeconomics task (shopping food items in a mock supermarket scenario).
Study NCT01730742 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Portion Size Task
Description: Participants are given a computer program that gives them the opportunity to choose the portions of a variety of food items that they would ideally like to consume
Study NCT01730742 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: After a night of wakefulness, a blood sample was taken to assess the level and efficacy of circulating neutrophils, as well as to assay blood serum and plasma for the presence of hormones involved in hunger such as oxytocin and ghrelin
Study NCT03470103 — intervention group
Intervention type: DRUG
Intervention: Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)
Description: Use of intravitreal aflibercept in routine clinical practice in Latin America
Study NCT03050047 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCD-100
Description: Anti-PD1 monoclonal antibody
Study NCT04996511 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PulseOn
Description: Postoperative HRV measurement
Study NCT02673268 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mastectomy
Study NCT02673268 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Da Vinci Robot Xi
Study NCT02553707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibandronate
Description: Participants will receive ibandronate 6 mg IV on Days 1, 2, and 3.
Study NCT01210144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gonal -f® [r-hFSH]
Description: On Day 2 of the menstrual cycle, a pre-defined fixed dose of 150 International Units (IU) per day of recombinant human follicle stimulating hormone (r-hFSH) will be administered until follicles are recruited and developed.
Study NCT01210144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ovitrelle® [r-hCG alfa]
Description: Ovulation triggering will be performed using a single injection of 250 microgram (mcg) recombinant human chorionic gonadotropin (r-hCG) alfa as soon as follicles satisfy the criteria for follicular development, that is at least 3 follicles greater than (>) 16 millimeter (mm), and with estradiol (E2) > 1 microgram per liter (mcg/L) if gonadotropin releasing hormone (GnRH) agonist will be used.
Study NCT01210144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gonadotropin-releasing hormone (GnRH) Agonist
Description: To prevent premature ovulation in participants undergoing a controlled ovarian stimulation (COS), 0.1 milligram (mg) GnRH agonist daily will be given after endometrial biopsy, 7 days after the peak day of luteinizing hormone (Day LH + 7) as per summary of product characteristics (SmPC), in long agonist protocol.
Study NCT01210144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gonadotropin-releasing hormone (GnRH) Antagonist
Description: To prevent premature ovulation in participants undergoing a COS, 0.25 mg GnRH antagonist daily will be given from Day 6 of Gonal-f® stimulation treatment as per SmPC, in multi-dose antagonist protocol.
Study NCT02456038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asfotase Alfa (ALXN1215)
Study NCT01800019 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine Replacement Therapy (NRT)
Study NCT01800019 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Study NCT02986659 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Study NCT01800019 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HIV Tailored Quit Smoking Counseling
Description: A cognitive behavioral therapy (CBT) oriented smoking cessation program tailored to HIV positive individuals.~People Living with HIV/AIDS (PHA) tailored Canadian HIV Quit Smoking Counseling Intervention. It consists of face-to-face counseling sessions with a trained smoking cessation counsellor at randomization, on the identified quit date, and then at weeks 4, 8, 12, and 24.
Study NCT04529850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: GC4419
Description: GC4419 60 Minute Infusion
Study NCT02986659 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Study NCT02986659 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study NCT02986659 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04529850 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiation therapy (IMRT)
Description: 2.0 to 2.2 Gy daily over 7 weeks
Study NCT04529850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 100mg/m2 once every 3 weeks or 40mg/m2 once weekly for 6-7 doses
Study NCT03339336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB074
Description: Administered as specified in the treatment arm.
Study NCT03339336 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as specified in the treatment arm.
Study NCT04977492 — intervention group
Intervention type: PROCEDURE
Intervention: extracapsular release of lateral retinaculum
Description: A new kind of surgery which releases the lateral retinaculum from outside the knee capsular, maintaining the structure of the knee capsular.
Study NCT03026933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KI1107 4 Capsules, QD
Description: KI1107 4 Capsules
Study NCT03026933 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin Calcium 20 MG, QD
Description: Rosuvastatin Calcium 20mg, QD
Study NCT01702532 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine
Description: Comparison of different dosage forms of nicotine
Study NCT01702532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine
Description: Comparison of different dosage forms of nicotine
Study NCT04012281 — intervention group
Intervention type: DEVICE
Intervention: Percutaneous coronary intervention
Description: PCI was performed using 2nd generation DES
Study NCT02271724 — intervention group
Intervention type: PROCEDURE
Intervention: Lumbar puncture
Description: Lumbar puncture for spinal fluid
Study NCT02271724 — intervention group
Intervention type: PROCEDURE
Intervention: Blood sample
Description: Blood sample
Study NCT01451242 — intervention group
Intervention type: OTHER
Intervention: no intervention is made
Description: no intervention is made
Study NCT03448939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S5G4T-1
Description: Once a day topical cream
Study NCT03448939 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: S5G4T-2
Description: Once a day topical cream
Study NCT03093051 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Unpinning Termination therapy
Description: Electrotherapy comprised of standard biphasic and monophasic pacing pulses
Study NCT04134520 — intervention group
Intervention type: DEVICE
Intervention: ProLung System
Description: Non-invasive bioconductance measurements
Study NCT01205074 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 13C Methacetin Breath Test
Study NCT01205074 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Grape fruit juice
Study NCT01205074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Non selective beta blocker - Propranolol
Study NCT01205074 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ethanol
Study NCT05136534 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: spinal anesthesia
Description: subarachnoid anesthesia with 2% hyperbaric pilicaine
Study NCT05136534 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: local anesthesia
Description: (Mepivacaine 2%) performed by the surgeon before skin incision
Study NCT01618019 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acid
Description: 5 capsules/day of either n-3 PUFA, containing 2.09 g eicosapentaenoic acid and 1.165 g docosahexaenoic acid
Study NCT01618019 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 5 capsules/day of placebo containing sunflower with oleic acid (DSM Nutritional products, Switzerland)
Study NCT03668730 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiation therapy
Description: Patients undergo low-dose OR standard dose IMRT based on their radiographic response to induction chemotherapy
Study NCT03668730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel liposome
Description: Patients receive Paclitaxel liposome by 135mg/m2 with a total of two cycles.
Study NCT03668730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Patients receive Cisplatin by 25mg/m2 on day1-day3 with a total of two cycles as induction chemotherapy ; patients receive cisplatin by 100mg/m2 with a total of three cycles as concurrent chemotherapy.
Study NCT03668730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: Patients receive 5-Fluorouracil by 3750mg/m2 civ120h with a total of three cycles.
Study NCT00422799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Once weekly for 3 weeks
Study NCT00422799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Intravenously once a week for the first and fourth weeks of a cycle
Study NCT01777243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2398852
Description: Unit dose strength: 100 mg/mL provided as 1 mL solution per vial. GSK2398852 dosage levels variable with the proposed starting dose level of GSK2398852 as 5 mg \[approximately equivalent to 0.1 mg/ kg\]. The next escalation dose levels are proposed as 1 mg/kg, 3 mg/kg, 10 mg/kg and 30 mg/kg.
Study NCT01777243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2315698
Description: Unit dose strength: 200 mg/mL stock to be diluted. GSK2315698 will be administered at variable dosed until the concentration of the serum amyloid P component monoclonal antibody (SAP mAb) has fallen below 100 ng/mL.
Study NCT04672512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CORT125329 lipid capsule formulation
Description: CORT125329 lipid capsule formulation 1 or 2 for oral administration
Study NCT04672512 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching CORT125329 lipid capsule formulation 1 or 2 for oral administration
Study NCT04672512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone tablet for oral administration
Study NCT01812382 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retapamulin Microdialysis
Description: After a 30 minutes equilibration period of the microdialysis procedure/infusion with normal saline solution, 50nanogram (ng)/mL Retapamulin injectable solution will be infused at a flow rate of 1.5 microliter/minute over a period of 90 minutes. The total dose perfused for each of the 3 microdialysis tubes will be 6.75ng.
Study NCT02183870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib
Description: 250mg crizotinib bid until end of treatment
Study NCT04139915 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dactolisib
Description: TORC1 inhibitor
Study NCT04139915 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule
Study NCT00323713 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Very low protein diet
Description: 0.3 g of proteins per kilo of body weight per day, supplemented with a mixture of essential aminoacids and chetoacids
Study NCT00323713 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low protein diet
Description: 0.6 g of protein per kilo of body weight per day
Study NCT02479997 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Indocyanine green
Description: ICG is cyanine dye used in medical diagnostics. It is used for determining cardiac output, hepatic function, and liver blood flow, and for ophthalmic angiography.~In this study, Investigator uses ICG as a fluorescent dye which is used in medicine as an indicator substance . And it will allow detection of SLN more convenientlty.
Study NCT02479997 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Radioisotope
Description: Nuclear medicine uses radiation to provide diagnostic information about the functioning of a person's specific organs, or to treat them. Diagnostic procedures using radioisotopes are now routine.
Study NCT01269814 — intervention group
Intervention type: PROCEDURE
Intervention: Gastroscopy
Description: Gastroscopy
Study NCT03394261 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Decision Aid
Description: PtDA-MAT will provide information on MAT treatment options and pros and cons of each treatment option, and will assess patients' preferred options.